Search results for "Cohort Study"

showing 10 items of 3811 documents

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

2018

Objectives We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART. Methods Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and normalized by CD4+ T cells. Linear correlation between pre-ART HIV DNA and other continuous markers (HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to s…

0301 basic medicineOncologyCD4-Positive T-LymphocytesMaleHIV InfectionsSettore MED/07chemistry.chemical_compoundHIV InfectionPharmacology (medical)ViralProspective StudiesProspective cohort studyAntiinfective agentAdult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; DNA Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Viral LoadMiddle AgedViral LoadvirologyHIV CD4Stavudinemedicine.anatomical_structureInfectious DiseasesTreatment Outcomehiv-1 t-lymphocytes virology blood hiv rna hiv dnaAnti-Retroviral AgentsCD4-Positive T-Lymphocyteblood hiv rnaCohorthiv dnaFemaleSurvival AnalysiViral loadARTHumanMicrobiology (medical)Adultmedicine.medical_specialtyAntiretroviral Therapy CD4 Lymphocyte Count StavudineT cellAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesInternal medicinemedicineHumanst-lymphocytesSurvival analysisPharmacologybusiness.industryProportional hazards modelHIVDNASurvival AnalysisCD4 Lymphocyte CountProspective Studie030104 developmental biologychemistryDNA ViralHIV-1Anti-Retroviral AgentbusinessDNA
researchProduct

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

2020

Simple Summary Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancer (RCC), with no data on its prevalence worldwide. No genotype-phenotype associations have been described. The aim of our study was to describe the genotypic and phenotypic features of the largest series of patients with HLRCC from Spain reported to date. Of 27 FH germline pathogenic variants, 12 were not previously reported in databases. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function varia…

0301 basic medicineOncologyCancer ResearchCancer cellsmedicine.disease_causeurologic and male genital diseases:Male Urogenital Diseases::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Male Urogenital Diseases::Carcinoma Renal Cell [DISEASES]<i>FH</i> gene0302 clinical medicineMalalties hereditàriesMissense mutationFH geneFH gene hereditary leiomyomatosis leiomyomas missense pathogenic variants renal cell cancerRenal cell cancerMutationKidney diseasesHereditary leiomyomatosis:Otros calificadores::Otros calificadores::/genética [Otros calificadores]:enfermedades urogenitales masculinas::neoplasias urogenitales::neoplasias urológicas::neoplasias renales::enfermedades urogenitales masculinas::carcinoma de células renales [ENFERMEDADES]leiomyomasmissense pathogenic variants renal cell cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRare diseases:Geographic Locations::Europe::Spain [GEOGRAPHICALS]Oncology030220 oncology & carcinogenesisCohortCèl·lules cancerosesMalalties raresRenal Cell CancersGenetic disordersmedicine.medical_specialtyMissense pathogenic variantsBiología Celularlcsh:RC254-282Article03 medical and health sciencesLeiomyomasInternal medicine:Other subheadings::Other subheadings::/genetics [Other subheadings]medicineRonyons - Malalties - Espanya:localizaciones geográficas::Europa (continente)::España [DENOMINACIONES GEOGRÁFICAS]business.industry:neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::leiomioma::leiomiomatosis [ENFERMEDADES]Retrospective cohort studymedicine.diseaseGenética030104 developmental biologyFumaraseClinical diagnosisHereditary leiomyomatosis and renal cell cancer syndromeMalalties del ronyó:Neoplasms::Neoplasms by Histologic Type::Neoplasms Connective and Soft Tissue::Neoplasms Muscle Tissue::Leiomyoma::Leiomyomatosis [DISEASES]hereditary leiomyomatosisbusiness
researchProduct

Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature

2016

BACKGROUND Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs. PATIENTS AND METHODS A systematic review of the published data was performed concerning the use of everolimus in extrapancreatic NET, with the aim of summarizing the current knowledge on its efficacy and tolerability. Moreover, the usefulness of everolimus was evaluated according to the different sites of the primary. RESULTS The present study included 22 different publications, including 874 patients and 4…

0301 basic medicineOncologyCancer ResearchLung NeoplasmsAdrenal Gland NeoplasmsColorectal NeoplasmNeuroendocrine tumorsSettore MED/13 - EndocrinologiaAntineoplastic Agent0302 clinical medicineEndocrinologyNeuroendocrine tumors; everolimus; extrapancreatic; efficacy; safetyProspective cohort studyNeuroendocrine TumorsEverolimuOncologyTolerability030220 oncology & carcinogenesisIleal NeoplasmSafetyColorectal Neoplasmsmedicine.drugHumanmedicine.medical_specialtyEfficacyAntineoplastic AgentsPheochromocytomaExtrapancreatic neuroendocrine tumorDisease-Free Survival03 medical and health sciencesNeuroendocrine tumorStomach NeoplasmsStomach NeoplasmInternal medicinemedicineHumansEverolimusThyroid NeoplasmsAdverse effectEverolimusbusiness.industryRetrospective cohort studymedicine.diseaseDiscontinuationCarcinoma NeuroendocrineClinical trialIleal NeoplasmsAdrenal Gland NeoplasmLung Neoplasm030104 developmental biologyEndocrinologybusiness
researchProduct

Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis

2018

Abstract Background Ki-67 is a marker of proliferating cells; in this meta-analysis we aimed to examine whether Ki-67 expression can predict recurrence rates of breast ductal carcinoma in situ (DCIS). Materials and Methods This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were sought in MEDLINE up to April 30, 2017. Random effects (DerSimonian–Laird) models were used for the calculation of pooled relative risk (RR) estimates; meta-regression analysis was also performed. Separate analyses were performed according to Ki-67 expression cutoff levels, invasiveness of recurrence,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsRisk Assessment03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansMeta-regressionBreastMastectomybiologybusiness.industryDuctal carcinomaPrognosismedicine.diseaseConfidence intervalCarcinoma Intraductal NoninfiltratingKi-67 Antigen030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMeta-analysisKi-67biology.proteinFemaleRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessCohort studyClinical Breast Cancer
researchProduct

Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab

2019

Immune checkpoint blockade is an emerging anticancer strategy, and Nivolumab is a human mAb to PD-1 that is used in the treatment of a number of different malignancies, including non-small cell lung cancer (NSCLC), kidney cancer, urothelial carcinoma and melanoma. Although the use of Nivolumab prolongs survival in a number of patients, this treatment is hampered by high cost. Therefore, the identification of predictive markers of response to treatment in patients is required. In this context, PD-1/PDL1 blockade antitumor effects occur through the reactivation of a pre-existing immune response, and the efficacy of these effects is strictly associated with the presence of necrosis, hypoxia an…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtySurvivalImmunology03 medical and health sciences0302 clinical medicineNon-small cell lung cancerInternal medicinemedicineProgression-free survivalLung cancerPathologicalProgrammed cell death protein 1business.industryMelanomaRetrospective cohort studyArticlesmedicine.diseaseBlockade030104 developmental biologyNivolumabOncologyTexture analysis030220 oncology & carcinogenesisNivolumabRadiomicbusinessKidney cancer
researchProduct

Copy number variations inDCC/18q andERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer

2017

We conducted a prospective study to assess the prognostic impact of selected copy number variations (CNVs) in stage II-III microsatellite stable (MSS) colon cancer. A total of 401 patients were included from 01/2004 to 01/2009. The CNVs in 8 selected target genes, DCC/18q, EGFR/7p, TP53/17p, BLK/8p, MYC/8q, APC/5q, ERBB2/17q, and STK6/20q, were detected using a quantitative multiplex polymerase chain reaction of short fluorescent fragment (QMPSF) method. The primary end-point was the impact of the CNVs on the 4-year disease-free survival (DFS). The recurrence rate at 4 years was 20.9%, corresponding to 14% stage II patients vs 31% stage III patients (p<0.0001). The 4-year DFS was significan…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryColorectal cancerHazard ratiomedicine.diseaseBioinformaticsConfidence interval3. Good health03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineChromosome instabilityMultiplex polymerase chain reactionMedicineCopy-number variationStage (cooking)businessProspective cohort studyInternational Journal of Cancer
researchProduct

Female-specific association among I, J and K mitochondrial genetic haplogroups and cancer:A longitudinal cohort study

2018

Recent studies highlighted the role of mitochondrial dysregulation in cancer, suggesting that the different mitochondrial haplogroups might play a role in tumorigenesis and risk of cancer development. Our aim is to investigate whether any mitochondrial haplogroups carried a significant higher risk of cancer development in a large prospective cohort of North American people. The haplogroup assignment was performed by a combination of sequencing and PCR-RFLP techniques. Our specific outcome of interest was the incidence of any cancer during follow-up period. Overall, 3222 participants were included in the analysis. Women having I, J, K haplogroup reported a significant higher incidence of can…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtygenetic structuresBiologymedicine.disease_causeDNA MitochondrialHaplogroupHaplogroupArticleCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsGeneticsmedicineHumansGenetic Predisposition to DiseaseLongitudinal StudiesLongitudinal cohortProspective cohort studyMolecular BiologyOncogenesisCancerCancer Screening Oncogenesis Mitochondrial HaplogroupIncidence (epidemiology)Cancermedicine.diseaseeye diseaseshumanitiesMitochondrial030104 developmental biologyHaplotypes030220 oncology & carcinogenesisScreeningCancer; Haplogroup; Mitochondrial; Oncogenesis; ScreeningFemaleCancer developmentCarcinogenesis
researchProduct

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

2019

Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line cabozantinib. A multicenter retrospective real-world study was conducted, involving 32 worldwide centers. A total of 237 patients with histologically confirmed clear-cell and non-clear-cell RCC who received cabozantinib as second- or third-line therapy for metastatic disease were included. We analyzed overall survival (OS), progression-free survival (PFS) and time-to-strategy failure (TTSF) using Kaplan&ndash

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyrenal cell carcinomaCabozantinibPrognosiContext (language use)urologic and male genital diseaseslcsh:RC254-282ArticlePazopanib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRenal cell carcinomacabozantinibInternal medicinemedicineProgression-free survivalCabozantinib; Nivolumab; Prognosis; Real-world data; Renal cell carcinoma; Targeted therapynivolumabreal-world databusiness.industrySunitinibRetrospective cohort studylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetargeted therapyAxitinib030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisprognosisbusinessmedicine.drugCancers
researchProduct

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.

2019

BackgroundIn this study based on the BRENDA data, we investigated the impact of endocrine ± chemotherapy for luminal A, nodal positive breast cancer on recurrence free (RFS) and overall survival (OS). In addition, we analysed if tumor size of luminal A breast cancer influences survival in patients with the same number of positive lymph nodes.MethodsIn this retrospective multi-centre cohort study data of 1376 nodal-positive patients with primary diagnosis of luminal A breast cancer during 2001-2008 were analysed. The results were stratified by therapy and adjusted by age, tumor size and number of affected lymph nodes.ResultsIn our study population, patients had a good to excellent prognosis …

0301 basic medicineOncologyDose-dense chemotherapyAdjuvant Chemotherapymedicine.medical_treatmentCancer Treatment0302 clinical medicineBreast TumorsMedicine and Health SciencesEndocrine TumorsMultidisciplinaryPharmaceuticsQREndocrine TherapyMiddle AgedPrognosisSurvival RateOncologyDocetaxelChemotherapy AdjuvantLymphatic Metastasis030220 oncology & carcinogenesisMedicineFemaleLymphAnatomyResearch Articlemedicine.drugClinical Oncologymedicine.medical_specialtyScienceBreast NeoplasmsDisease-Free SurvivalLymphatic SystemCancer Chemotherapy03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancermedicineHumansChemotherapyEndocrine systemSurvival rateAgedRetrospective StudiesChemotherapybusiness.industryBiology and Life SciencesCancers and NeoplasmsRetrospective cohort studymedicine.disease030104 developmental biologyLymph NodesClinical MedicinebusinessPLoS ONE
researchProduct

The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.

2017

&lt;b&gt;&lt;i&gt;Background/Aim:&lt;/i&gt;&lt;/b&gt; Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. &lt;b&gt;&lt;i&gt;Subjects and Methods:&lt;/i&gt;&lt;/b&gt; In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Radium-223 was well tolerated, with a m…

0301 basic medicineOncologyDrugRadium-223MaleCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAntineoplastic AgentsBone NeoplasmsDocetaxel03 medical and health sciencesProstate cancer0302 clinical medicineQuality of lifeInternal medicinemedicineHumansmedia_commonAgedRetrospective StudiesAged 80 and overRadioisotopesbusiness.industryBone metastasisRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseProstatic Neoplasms Castration-Resistant030104 developmental biologyOncologyDocetaxelItaly030220 oncology & carcinogenesisQuality of LifeAlkaline phosphatasePrednisoneTaxoidsRadium-223 Bone metastasis Prostate cancer Radiopharmaceuticals Metastatic castration-resistant prostate cancer Quality of Lifebusinessmedicine.drugRadiumOncology
researchProduct